Effect of RAS Blockers on CKD Progression in Elderly Patients With Non Proteinuric Nephropathies (PROERCAN01)

• Status: Recruiting
• Trial end date: 2022-12-01
• Target enrollment: 0
• Participant gender: All

Summary

This study evaluates the effect of renin-angiotensin blockers on chronic kidney disease progression in elderly (>65 years old) patients with non-proteinuric nephropathies. Half of the patients will receive angiotensin converting enzyme inhibitors, while the other half will not receive them. Renal function, proteinuria and cardiovascular events will be follow up during a three year period.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Hospital General Universitario Gregorio Marañon
• Treatments: Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Enzyme Inhibitors; Furosemide; Lercanidipine; Lisinopril

Criteria

Inclusion Criteria:

• Age >65 years

• Chronic kidney disease stage 3 or 4 (GFR measured by CKD-EPI 15-59 ml/min/1,73 m2)

• Albumine/creatinine index < 30 mg/g in simple urine sample or albuminuria < 30 mg/day in 24-hour urine sample.

• Previous hypertensive treatment::

1. patients who have not received RAS blockers in the three months prior to inclusion can be included

2. patients who are receiving RAS blockers could be included after one month washout period

Exclusion Criteria:

• Diabetes mellitus (type 1 or 2)

• Glomerulopathy

• Chronic heart failure or coronary heart disease

• Poorly controlled hypertension (>160/100 mmHg)

• Monorrenal

• Active malignant neoplasia (except skin cancer different from melanoma). Patients who have been free of malignancy for the last 5 years could be included.

• Chronic symptomatic or not controlled inflammatory disease (eg rheumatoid arthritis, Chron disease, ulcerative colitis or systemic lupus erythematosus)

• Chronic liver disease

• Allergy or intolerance to renin angiotensin system blockers or calcium channel blockers

• Hepatitis B, C or HIV infection

• Immunosuppressive treatment in the 3 months prior to inclusion

• Hospitalization of any cause in the three months prior to inclusion

• Rapidly progressive kidney disease (decline in GFR >5ml/min/1.73 m2/year)

• Inability to sign the informed consent